Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07174401

Rocklatan Retinal Perfusion OCT Study

The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Casey Eye Institute - Oregon Health & Science University

Portland, Oregon, 97239, United States

Location contact

Aiyin Chen, MD

SUB_INVESTIGATOR

Chinmay Deshpande, MS Optom

CONTACT

[email protected]

503-494-9628

Denzil Romfh, OD

CONTACT

[email protected]

503-494-4351

Eliesa Ing, MD

SUB_INVESTIGATOR

Michael Gale, MD

SUB_INVESTIGATOR

Ou Tan, PhD

SUB_INVESTIGATOR

Yali Jia, PhD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with both eyes with open angle glaucoma.
  • Abnormal VF (glaucomatous pattern with PSD abnormal at p<0.05 or GHT outside normal limits) on most recent two clinic visits on chart review
  • Glaucomatous disc abnormality on chart review and confirmed on baseline disc photograph
  • Overall average NFL thickness > 55 μm measured by Heidelberg Spectralis OCT -Glaucoma Module Premium Edition (chart review), consistent with early glaucoma
  • NFLP-CD deficit (below 5 percentile of normal) in any of the 8 sectors on the initial baseline visit
  • The difference in baseline NFLP-CD between the left and right eye should be less than 5% (% of area).
  • IOP >= 17 mm Hg on the most recent two clinic visits (chart review) after monotherapy with latanoprost in both eyes.

Exclusion criteria

  • Best corrected visual acuity worse than 20/30 on chart review of most recent clinic visit
  • Age < 21 years at baseline
  • Eye disease that could affect VF, NFL thickness, or NFLP (e.g., visually significant cataract, AMD, diabetic retinopathy, and optic neuropathy) at any study visit
  • OCT and OCTA scans not meeting quality criteria at baseline
  • Inability to cooperate with study procedures
  • Inability to commit to the study visits

Treatment and study plan

Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.

Drug

The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.

Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.

Device

One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.

Primary outcomes

  1. Nerve Fiber Layer Plexus Capillary Density (NFLP CD)

    Time frame: From enrollment to end of treatment at 11-12 months

    The primary outcome measure will be change in the overall peripapillary NFLP CD measured at 6 months and 11-12 month endpoint visits compared to baseline values.

Secondary outcomes

  1. Total Retinal Blood Flow (TRBF)

    Time frame: From enrollment to end of treatment at 11-12 months

    Secondary outcome measures will include change in the TRBF measured at 6 months or 11-12 month endpoint visits compared to baseline.

Study contacts

Contact information is provided by the study sponsor or research team.

Chinmay Deshpande, MS Optom

CONTACT

[email protected]

503-494-9628

Denzil Romfh, OD

CONTACT

[email protected]

503-494-4351

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Collaborators

  • Alcon Research

Registry information

Official study title

Rocklatan Trial With Optical Coherence Tomography Study of Retinal Perfusion

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Sep 16, 2025
Registry last updated
Dec 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.